Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C

Completed

Conditions studied: Chronic Hepatitis C, Obesity

In brief

The response rate to interferon-based anti-viral therapy for chronic hepatitis C is lower in patients who are obese. However, it is not clear whether this is related to suboptimal dosing of the medication or alterated response in obese patients. Alterated immune response had been reported in obese patients. The goal of current study is to determine the immune response to interferon in obese compared to non-obese chronic hepatitis C in an tissue culture system.

Key facts

Study ID

NCT00322179

Run by

Palo Alto Veterans Institute for Research

People needed

22

Starts

2005-11-01

Expected to finish

2008-11-01

Last updated by the study team

2020-03-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• obese (weight > 85kg and BMI>30) or non-obese patients (<75kg and BMI <25) with chronic Hepatitis C
• Chronic Hepatitis C infection with documented HCV RNA
• Body habitat either as obese or non-obese as defined above
• Currently not under IFN therapy
• Non-African American

You may not qualify if…

• Body habitat neither obese or non-obese as defined for the purpose of this study
• Unable to give consent
• On immunomodulatory agents such as prednisone
• Active infection other than Hepatitis C
• Co-infection with HBV or HIV
• Active or excessive alcohol use
• Other cause of chronic Hepatitis

Where it is running

• VA Palo Alto Health Care System — Palo Alto, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.